The clinical trial, set to begin in June 2025, will evaluate the capabilities of the NeuroHawk device to diagnose TBI and localize brain hemorrhage, offering critical insights in high-pressure environments. With a period of performance of 30 months, this contract marks the second direct military funding the company has received, with the first coming through the Medical Technology Enterprise Consortium (MTEC) to build the NeuroHawk technology and derive initial algorithms for hemorrhage detection.

“We are honored to receive this contract from CDMRP as it recognizes the potential of our technology to address a significant unmet need for both military personnel and civilian patients,” said Geoff Klass, CEO of Sense Neuro Diagnostics. “The NeuroHawk is designed for use in field conditions, allowing for rapid detection and monitoring of brain injuries. With this support, we are poised to advance the development and deployment of life-saving technology.”

Meeting the Critical Need for Rapid TBI Diag